GIST Resources

Housing Resources For Cancer Patients & Families

Financial Support for Cancer Patients

Blueprint Medicines Corporation's AYVAKIT™ (avapritinib)

The FDA granted a full approval to AYVAKIT™ (avapritinib) based on efficacy results from the Phase 1 NAVIGATOR clinical trial, as well as combined safety results from multiple clinical trials for avapritinib. Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy announced that AYVAKIT™ (avapritinib) is used for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT is the first precision therapy approved to treat a genomically defined population of patients with GIST. Blueprint Medicines plans to make AYVAKIT available in the U.S. within a week.

For more detailed information on AYVAKIT™ (avapritinib), click on the following link: